| PRECLINICAL | evidence | Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. | Retatrutide | — | 2025-11-23 |
| PRECLINICAL | evidence | Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. | Retatrutide | Weight & fat loss | 2025-11-05 |
| PRECLINICAL | evidence | Weight management treatment in obesity. | retatrutida | Weight & fat loss | 2025-11-01 |
| PRECLINICAL | evidence | Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. | Retatrutide | Weight & fat loss · n = 29506 | 2025-11-01 |
| PRECLINICAL | evidence | Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies. | Retatrutide | — | 2025-11-01 |
| PRECLINICAL | evidence | Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes. | Retatrutide | — | 2025-11-01 |
| PRECLINICAL | evidence | Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects. | Retatrutide | — | 2025-10-09 |
| PRECLINICAL | evidence | Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. | Retatrutide | Weight & fat loss | 2025-10-07 |
| PRECLINICAL | evidence | Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight. | Retatrutide | — | 2025-10-01 |
| PRECLINICAL | evidence | Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. | Retatrutide | Glycemic control · n = 2600 | 2025-09-16 |
| PRECLINICAL | evidence | Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs. | Retatrutide | — | 2025-09-15 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies. | Retatrutide | Weight & fat loss | 2025-09-01 |
| PRECLINICAL | evidence | The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review. | Retatrutide | — | 2025-09-01 |
| PRECLINICAL | evidence | Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. | Retatrutide | Glycemic control · n = 66232 | 2025-09-01 |
| PRECLINICAL | evidence | Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis. | Retatrutide | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. | Retatrutide | — | 2025-08-26 |
| PRECLINICAL | evidence | Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies. | Retatrutide | — | 2025-07-28 |
| PRECLINICAL | evidence | Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. | Retatrutide | Weight & fat loss | 2025-07-01 |
| PRECLINICAL | evidence | Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease. | Retatrutide | Weight & fat loss | 2025-07-01 |
| PRECLINICAL | evidence | Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis. | Retatrutide | Glycemic control | 2025-06-01 |
| PRECLINICAL | evidence | The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. | Retatrutide | — | 2025-06-01 |
| PRECLINICAL | evidence | Retatrutide-A Game Changer in Obesity Pharmacotherapy. | Retatrutide | Weight & fat loss | 2025-05-30 |
| PRECLINICAL | evidence | [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. | Retatrutide | Glycemic control | 2025-05-01 |
| PRECLINICAL | evidence | Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. | Retatrutide | Glycemic control | 2025-05-01 |
| PRECLINICAL | evidence | Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials. | Retatrutide | — | 2025-04-01 |
| PRECLINICAL | evidence | Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment. | Retatrutide | Weight & fat loss | 2025-03-24 |
| PRECLINICAL | evidence | What is the pipeline for future medications for obesity? | Retatrutide | Weight & fat loss | 2025-03-01 |
| PRECLINICAL | evidence | Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. | Retatrutide | Weight & fat loss | 2025-03-01 |
| PRECLINICAL | evidence | Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials. | Retatrutide | — | 2025-03-01 |
| PRECLINICAL | evidence | The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. | Retatrutide | Weight & fat loss | 2025-03-01 |
| PRECLINICAL | evidence | Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. | Retatrutide | — | 2025-03-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. | Retatrutide | Weight & fat loss · n = 15491 | 2025-02-01 |
| PRECLINICAL | evidence | Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis. | Retatrutide | Glycemic control · n = 9165 | 2025-01-01 |
| PRECLINICAL | evidence | Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations. | Retatrutide | — | 2025-01-01 |
| PRECLINICAL | evidence | Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology. | Retatrutide | Weight & fat loss | 2025-01-01 |
| PRECLINICAL | evidence | Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. | Retatrutide | Weight & fat loss | 2025-01-01 |
| PRECLINICAL | evidence | Emerging pharmacotherapies for obesity: A systematic review. | Retatrutide | Weight & fat loss | 2025-01-01 |
| PRECLINICAL | evidence | Triple Agonism Based Therapies for Obesity. | Retatrutide | — | 2025-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. | LY3437943 | Weight & fat loss | 2025-01-01 |
| PRECLINICAL | evidence | Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. | Retatrutide | — | 2025-01-01 |
| PRECLINICAL | evidence | Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. | LY3437943 | — | 2025-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. | Retatrutide | — | 2025-01-01 |
| PRECLINICAL | evidence | The power of three: Retatrutide's role in modern obesity and diabetes therapy. | Retatrutide | — | 2024-12-15 |
| PRECLINICAL | evidence | The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. | Retatrutide | Weight & fat loss | 2024-12-01 |
| PRECLINICAL | evidence | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. | Retatrutide | — | 2024-12-01 |
| PRECLINICAL | evidence | Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. | Retatrutide | Weight & fat loss | 2024-12-01 |
| PRECLINICAL | evidence | The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. | LY3437943 | — | 2024-12-01 |
| PRECLINICAL | evidence | Why are we still in need for novel anti-obesity medications? | Retatrutide | — | 2024-12-01 |
| PRECLINICAL | evidence | Incretin-based therapies for the treatment of obesity-related diseases. | LY3437943 | — | 2024-11-06 |
| PRECLINICAL | evidence | Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. | Retatrutide | Glycemic control | 2024-11-01 |